Status:
COMPLETED
Medical Treatment in Ectopic Tubal Pregnancy
Lead Sponsor:
Nishtar Medical University
Conditions:
Ectopic Pregnancy
Eligibility:
FEMALE
20-35 years
Phase:
NA
Brief Summary
Ectopic pregnancy (EP) is estimated to be responsible for approximately 20% of all pregnancy-related mortality and 46% early pregnancy mortality.1 Hemodynamically stable women with EP are frequently m...
Detailed Description
Literature reports multiple dosage regimens of MTX to be associated with increased rates of side effects. Single dose protocol has good compliance and fewer side effects but is linked with lower succe...
Eligibility Criteria
Inclusion
- Diagnosis of tubal ectopic pregnancy.
- Pre-treatment beta-human chorionic gonadotrophin (β-hCG) level below 1500 mIU/ml.
- Gestational sac with largest diameter as 4cm.
- Willing to take methotrexate treatment.
- Willing to follow up.
Exclusion
- Heterotrophic pregnancy
- Persistent tubal pregnancy
- Embryonic cardiac motion
- Suspected tubal rupture
- Past history of harmful effects of methotrexate treatment on organ functions.
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05208034
Start Date
January 1 2020
End Date
July 30 2021
Last Update
February 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nishtar Medical University Hospital
Multan Khurd, Pu, Pakistan, 66000